Evidence map›Paper›PMID 36434570›Full record

ArticleBMC urology2022

Diagnostic performance of an immunoassay based on urine exfoliated cell enrichment nanotechnology for upper tract urothelial carcinoma: a retrospective, monocentric study.

Xin Wang, Shiwei Zhang, Lang Wu, Baofu Feng, Hongwei Shen, Yuanyuan Gu, Qun Zhang, Feng Fang, Rong Yang, Hongqian Guo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Xin Wang *Department of Urology, Institute of Urology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing University, 321 Zhongshan Rd, 210008, Nanjing, Jiangsu, China.
Shiwei Zhang *Department of Urology, Institute of Urology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing University, 321 Zhongshan Rd, 210008, Nanjing, Jiangsu, China.
Lang Wu *PerMed Biomedicine Institute, 201321, Shanghai, China.
Baofu FengDepartment of Urology, Institute of Urology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing University, 321 Zhongshan Rd, 210008, Nanjing, Jiangsu, China.
Hongwei ShenDepartment of Urology, Institute of Urology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing University, 321 Zhongshan Rd, 210008, Nanjing, Jiangsu, China.
Yuanyuan GuPerMed Biomedicine Institute, 201321, Shanghai, China.
Qun ZhangPerMed Biomedicine Institute, 201321, Shanghai, China.
Feng FangDepartment of Pharmacology, Nanjing Medical University, 210000, Nanjing, Jiangsu, China.
Rong YangDepartment of Urology, Institute of Urology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing University, 321 Zhongshan Rd, 210008, Nanjing, Jiangsu, China. doctoryr@gmail.com.
Hongqian GuoDepartment of Urology, Institute of Urology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing University, 321 Zhongshan Rd, 210008, Nanjing, Jiangsu, China. dr.ghq@nju.edu.cn.
Nanjing University · CNInstitute for Biomedicine · ITNanjing Drum Tower Hospital · CNNanjing Medical University · CN

Funding

National Natural Science Foundation of China 81772727 and 81772710The Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Key Medical Discipline (Laboratory) ZDXKB2016014
6 · The paper itself

Abstract

backgroundNoninvasively urine-based diagnostic modalities for upper urinary tract urothelial carcinoma (UTUC) were still lacking. We evaluated the diagnostic value of our previously developed urine-based assay (UTC assay) in UTUC.

methodsWe retrospectively analyzed 90 patients with suspected UTUC and 40 donors without UTUC. Voided urine specimens were analyzed by UTC assay and fluorescence in situ hybridization (FISH). The performance of UTC assay and FISH was compared among the 60 histologically proven UTUC patients and the 40 donors with benign disease.

resultsOf the 60 UTUCs, there were 8 low-grade and 52 high-grade cases. Overall sensitivity for UTC assay and FISH were 85% and 73.3%, respectively (P = 0.116). Specificities for UTC assay and FISH were 92.5% and 95%, respectively (P = ns.). By grade, sensitivities of UTC assay and FISH were 87.5% vs. 37.5% for low-grade (P = 0.119), and 84.6% vs. 78.8% for high- grade UTUC (P = 0.446), respectively. By stage, UTC assay showed significantly higher sensitivity than FISH for detecting non-muscle-invasive UTUC, which were 88.5% vs. 61.5%, respectively (P = 0.025).

conclusionUTC assay has good performance for the non-invasive diagnosis of UTUC. UTC assay may improve the diagnosis and surveillance of low-grade or superficial UTUC.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsHumansImmunoassayIn Situ Hybridization, FluorescenceNanotechnologyRetrospective StudiesFISHImmunocytologyUpper urinary tractUrineUrothelial carcinoma

Identifiers

PMID36434570
PMCPMC9700989
OpenAlexW4309961556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.